XClose

Queen Square Centre for Neuromuscular Diseases

Home
Menu

Study of IgPro20 in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in subjects completing study IgPro20_3004

Sponsor / Funder CSL Behring
CI Dr Michael Lunn
UK sites London Queen Square
Contact details michael.lunn@uclh.nhs.uk
More information

The PATH study was a double-blinded trial of SCIG. This is an extension of the PATH study.

Trial information

This is an open-label prospective, multi-centre extension study for patients who have participated in the PATH study.

Primary objective

To investigate safety and efficacy of the long-term treatment of CIDP with IgPro20.

Patients may either transition directly from the PATH study to the extension or with an interval.

Patients who received IgG between studies should be enrolled within 1 week after the last administration of IgG.

The treatment duration will be up to 48 weeks, followed by a completion visit (week 49).